In the matter of Mayne Pharma Group Limited

In the case concerning Mayne Pharma Group Limited, the court was presented with an application for curative orders under section 1322(4)(c) of the Corporations Act 2001. The primary issue at hand was whether the corporation could be relieved from its liability due to a failure to provide timely notice of a share buy-back. The matter was heard in the Federal Court of Australia.

The central legal question revolved around the potential for granting an extension of time to rectify the failure to give notice of the share buy-back within the statutory timeframe. Specifically, the court had to determine if relief could be granted in the absence of any substantial injustice arising from the delay in notification. This involved assessing whether the delay had any significant impact on the rights of shareholders or the integrity of the corporate process.

The court deliberated on the statutory provisions and relevant case law, concluding that the delay in notification did not result in any substantial injustice. Consequently, the court found that the corporation was entitled to relief from its liability. The decision was based on the absence of any material harm caused by the delay, thereby justifying the granting of curative orders.

The final orders of the court allowed for the extension of time for the corporation to provide the necessary notice of the share buy-back, thereby absolving the corporation from its liability for the initial failure to comply with the statutory timeframe. This decision underscores the importance of assessing the impact of delays in corporate processes when considering applications for relief under the Corporations Act.